Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

4D Molecular Therapeutics announced the enrollment of the first patients in the Phase 3 clinical trial, 4FRONT-1, for its product 4D-150, aimed at treating wet age-related macular degeneration (AMD).

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence ...

Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2CTx-1301 is the First, True, Once-Daily Stimulant Medication to ...

today announced the initiation of the VERSATILE-003 Phase 3 clinical trial. The trial is now open to patient enrollment. “We are thrilled to share that the first trial site has been initiated ...

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous ...

Neumora halted one trial of its depression drug navacaprant and paused a pair of late-stage studies as it tries to learn from ...